Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT06974838
Recruiting Not applicable

Explore the Therapeutic Effect of Theta Burst Stimulation on Emotion Regulation in Autism With Minimally Verbal Ability or Intellectual Disability

NCT06974838 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Chang Gung Memorial Hospital
Phase
Not applicable
Started
2025-08-08
Last updated
2026-09-16

Condition(s) studied

Autism Spectrum DisorderMinimally Verbal AbilityIntellectual Disability

Investigational drug(s) / intervention(s)

intermittent theta burst stimulation

intermittent theta burst stimulation: stimulatory protocol

Study summary

The investigator would like to investigate the impact of theta-burst stimulation over left DLPFC in autism with minimally verbal ability or intellectual disability

Eligibility

Sex
ALL
Min age
8 Years
Max age
30 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of autism spectrum disorder, confirmed by DSM-5. * Individuals with minimal verbal ability or intellectual disability (FSIQ \< 70). Exclusion Criteria: * Current or past severe neurological disorders, such as epilepsy, or significant visual or hearing impairments. * Current or past severe systemic diseases, such as cardiovascular disease, diabetes, or multiple sclerosis. * History of severe brain injury. * Presence of implanted metal devices, such as a pacemaker or medication pump. * Current or past severe psychiatric disorders, such as schizophrenia, bipolar disorder, or major depressive disorder. * Pregnancy. * Significant brain abnormalities, such as intracranial space-occupying lesions. * Family history of epilepsy. * History of febrile seizures. * Concurrent use of medications that increase the risk of seizures. * Sleep disorders during rTMS procedures. * Skin lesions or trauma at the stimulation site. * Deemed ineligible by the principal investigator (PI). * Participation in another clinical trial within the past month. * Suicidal ideation or suicide attempts within the past year.

Primary outcome measure(s)

  • Total Scores of Aberrant Behavior Checklist — Baseline, Week 4, Week 8 and Week 12
    Aberrant Behavior Checklist is a parents' report questionnaire for aberrant behavior. The lower scores stand for less aberrant behavior.
  • Total Scores of Emotional Dysregulation Inventory — Baseline, Week 4, Week 8 and Week 12
    Emotional Dysregulation Inventory is a parents' report questionnaire for emotional dysregulation. The lower scores stand for better emotional regulation.
  • Total Scores of Child Behavior Checklist — Baseline, Week 4, Week 8 and Week 12
    Child Behavior Checklist is a parents' report questionnaire for behavioral and emotional problems. The lower scores stand for better behavioral and emotional regulation.

Trial sites (1)

FacilityCityRegionStatus
Chang Gung Memorial Hospital Taoyuan Taiwan Recruiting

More Chang Gung Memorial Hospital trials in Taiwan

Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC Recruiting
Fractional Exhaled Nitric Oxide and Exacerbations of COPD Starting soon
Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores Recruiting
Dendritic Cell-immunotherapy for Advanced Hepatocellular Carcinoma Active, not recruiting
Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma Recruiting

Other trials for the same condition

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder. Recruiting
Somatic Symptoms in Autism Spectrum Disorder: Data Integration Active, not recruiting
Social Robots and Board Games for Children With Autism Spectrum Disorder Recruiting
Development and Validation of the Observatory Battery of Common Eye Disorders for Adults With Intellectual Disability Recruiting
Social Skills Training Group Effectiveness in Adolescents With Autism Spectrum Disorder Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06974838 on ClinicalTrials.gov ↗ ← All trials in Taiwan